333 related articles for article (PubMed ID: 31015884)
1. Real-World Evidence of Safety and Efficacy of Carboplatin plus Nanoparticle Albumin-Bound Paclitaxel in Patients with Advanced Non-Small-Cell Lung Cancer and Preexisting Interstitial Lung Disease: A Retrospective Study.
Araya T; Kita T; Ueda T; Terada N; Sakai T; Yamamura K; Kurokawa K; Uchida Y; Sone T; Kimura H; Kasahara K
Can Respir J; 2019; 2019():5315903. PubMed ID: 31015884
[TBL] [Abstract][Full Text] [Related]
2. A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302).
Asahina H; Oizumi S; Takamura K; Harada T; Harada M; Yokouchi H; Kanazawa K; Fujita Y; Kojima T; Sugaya F; Tanaka H; Honda R; Kikuchi E; Ikari T; Ogi T; Shimizu K; Suzuki M; Konno S; Dosaka-Akita H; Isobe H; Nishimura M;
Lung Cancer; 2019 Dec; 138():65-71. PubMed ID: 31654836
[TBL] [Abstract][Full Text] [Related]
3. The safety and efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel in the treatment of non-small cell lung cancer patients with interstitial lung disease.
Yasuda Y; Hattori Y; Tohnai R; Ito S; Kawa Y; Kono Y; Urata Y; Nogami M; Takenaka D; Negoro S; Satouchi M
Jpn J Clin Oncol; 2018 Jan; 48(1):89-93. PubMed ID: 29036303
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of nab-paclitaxel + carboplatin for patients with non-small-cell lung cancer and interstitial lung disease.
Kenmotsu H; Yoh K; Mori K; Ono A; Baba T; Fujiwara Y; Yamaguchi O; Ko R; Okamoto H; Yamamoto N; Ninomiya T; Ogura T; Kato T
Cancer Sci; 2019 Dec; 110(12):3738-3745. PubMed ID: 31608537
[TBL] [Abstract][Full Text] [Related]
5. A phase II feasibility study of carboplatin and nab-paclitaxel for advanced non-small cell lung cancer patients with interstitial lung disease (YLOG0114).
Sakashita H; Uchibori K; Jin Y; Tsutsui T; Honda T; Sakakibara R; Mitsumura T; Nukui Y; Shirai T; Masuo M; Suhara K; Furusawa H; Yamashita T; Ohba T; Saito K; Takagiwa J; Miyashita Y; Inase N; Miyazaki Y
Thorac Cancer; 2022 May; 13(9):1267-1275. PubMed ID: 35322551
[TBL] [Abstract][Full Text] [Related]
6. The Safety and Efficacy of Treatment with Nab-paclitaxel and Carboplatin for Patients with Advanced Squamous Non-small Cell Lung Cancer Concurrent with Idiopathic Interstitial Pneumonias.
Fujita T; Hiroishi T; Shikano K; Yanagisawa A; Hayama N; Amano H; Nakamura M; Hirano S; Tabeta H; Nakamura S
Intern Med; 2018 Jul; 57(13):1827-1832. PubMed ID: 29434143
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patients.
Tanaka M; Hattori Y; Ishii T; Tohnai R; Itoh S; Kawa Y; Kono Y; Urata Y; Satouchi M
Respir Investig; 2020 Jul; 58(4):269-274. PubMed ID: 32111518
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study.
Sekine A; Satoh H; Baba T; Ikeda S; Okuda R; Shinohara T; Komatsu S; Hagiwara E; Iwasawa T; Ogura T; Kato T
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1245-52. PubMed ID: 27130459
[TBL] [Abstract][Full Text] [Related]
9. The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease.
Shimizu R; Fujimoto D; Kato R; Otoshi T; Kawamura T; Tamai K; Matsumoto T; Nagata K; Otsuka K; Nakagawa A; Otsuka K; Katakami N; Tomii K
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1159-66. PubMed ID: 25245821
[TBL] [Abstract][Full Text] [Related]
10. Anticancer drug treatment for advanced lung cancer with interstitial lung disease.
Otsubo K; Okamoto I; Hamada N; Nakanishi Y
Respir Investig; 2018 Jul; 56(4):307-311. PubMed ID: 29764748
[TBL] [Abstract][Full Text] [Related]
11. Carboplatin plus weekly nanoparticle albumin-bound paclitaxel in elderly patients with previously untreated advanced squamous non-small-cell lung cancer selected based on Mini Nutritional Assessment short-form scores: a multicenter phase 2 study.
Shiroyama T; Tamiya M; Minami S; Takata S; Masuhiro K; Futami-Nishijima Y; Uenami T; Mori M; Koba T; Matsuki T; Takimoto T; Suzuki H; Okamoto N; Komuta K; Hirashima T; Kumanogoh A; Kijima T
Cancer Chemother Pharmacol; 2017 Sep; 80(3):461-467. PubMed ID: 28688052
[TBL] [Abstract][Full Text] [Related]
12. Albumin-Bound Paclitaxel: A Review in Non-Small Cell Lung Cancer.
Blair HA; Deeks ED
Drugs; 2015 Nov; 75(17):2017-24. PubMed ID: 26541764
[TBL] [Abstract][Full Text] [Related]
13. A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer.
Socinski MA; Manikhas GM; Stroyakovsky DL; Makhson AN; Cheporov SV; Orlov SV; Yablonsky PK; Bhar P; Iglesias J
J Thorac Oncol; 2010 Jun; 5(6):852-61. PubMed ID: 20521351
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of nanoparticle albumin-bound paclitaxel in non-small cell lung cancer: a systematic review and meta-analysis.
Tan H; Hu J; Liu S
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):268-277. PubMed ID: 30600739
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L
J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of carboplatin plus nab-paclitaxel for treating advanced non-small-cell lung cancer with interstitial lung disease.
Niwa H; Nakahara Y; Yokoba M; Mitsufuji H; Sasaki J; Masuda N
Mol Clin Oncol; 2017 Oct; 7(4):604-608. PubMed ID: 28855994
[TBL] [Abstract][Full Text] [Related]
17. First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Results of the NEPTUN study.
Dechow T; Riera-Knorrenschild J; Hackanson B; Janssen J; Schulz H; Chiabudini M; Fischer von Weikersthal L; Budweiser S; Nacke A; Taeuscher D; Welslau M; Potthoff K
Cancer Med; 2021 Nov; 10(22):8127-8137. PubMed ID: 34668662
[TBL] [Abstract][Full Text] [Related]
18. Treatment Rationale and Design for J-SONIC: A Randomized Study of Carboplatin Plus Nab-paclitaxel With or Without Nintedanib for Advanced Non-Small-cell Lung Cancer With Idiopathic Pulmonary Fibrosis.
Otsubo K; Kishimoto J; Kenmotsu H; Minegishi Y; Ichihara E; Shiraki A; Kato T; Atagi S; Horinouchi H; Ando M; Kondoh Y; Kusumoto M; Ichikado K; Yamamoto N; Nakanishi Y; Okamoto I
Clin Lung Cancer; 2018 Jan; 19(1):e5-e9. PubMed ID: 28687482
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy and Safety of Carboplatin/Nanoparticle Albumin-Bound Paclitaxel Combination Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer or Recurrent Non-Small-Cell Lung Cancer Following Surgery].
Shimabukuro I; Noguchi S; Uyama K; Torii R; Ishimoto H; Yoshii C; Tanaka F; Yatera K; Mukae H
Gan To Kagaku Ryoho; 2018 Sep; 45(9):1305-1310. PubMed ID: 30237372
[TBL] [Abstract][Full Text] [Related]
20. A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease.
Hanibuchi M; Kakiuchi S; Atagi S; Ogushi F; Shimizu E; Haku T; Toyoda Y; Azuma M; Kondo M; Kawano H; Otsuka K; Sakaguchi S; Nokihara H; Goto H; Nishioka Y
Lung Cancer; 2018 Nov; 125():93-99. PubMed ID: 30429044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
